J.P. Morgan Global China Summit takeaways: constructive on technology and healthcare, cautious on gas utilities

Overview

This is an email-style summary from J.P. Morgan Asia Pacific Equity Research focused on China and Hong Kong first-to-market/headline research updates. The core content comes from the 2026 J.P. Morgan Global China Summit, healthcare field research, technology AI enabler research, and a number of company and industry view updates. Overall, it is not a deep-dive report on a single company, but rather a compilation of conference takeaways and research entry points across multiple industries and names.

Core views

The main message of the report is that China’s growth resilience is better than expected and structural stories remain intact, but sector divergence is significant. Within the technology chain, domestic AI chips, WFE, and OSAT are greater beneficiaries, while the Android handset supply chain and downstream consumer electronics margins face pressure from upstream price increases; in healthcare, AI drug discovery, innovative pipelines, BD, and advanced medical technologies are enhancing the sector’s global appeal; HashKey is supported by trading volume, margin recovery, and RWA/stablecoin themes, leading to a more positive view; gas utilities remain cautious due to uncertainties around sales volume, connections, and costs.

Analysis framework

The report uses conference takeaways and company management discussions, linking summit one-on-ones, industry fieldwork, company meetings, ASCO abstract observations, scenario analysis, and valuation/rating updates to form short- to medium-term views on multi-industry themes and individual stocks.

Methodology notes

• Conference takeawaysGlobal China Summit feedback synthesis

  Identify industry momentum and company catalysts through participating companies, investor feedback, and management discussions at the summit.

  The report summarizes company meetings and thematic discussions from the May 20-22 Global China Summit to assess growth resilience, structural opportunities, rating changes, and future watchpoints.

• Industry researchTechnology AI enabler research

  Assess beneficiaries and pressured segments across AI chips, WFE, OSAT, memory, wafer foundries, and the consumer electronics supply chain.

  The report differentiates among impacts from upstream material and service price increases, domestic AI chip ramp-up, potential upside from the iPhone supply chain, and continuing pressure on Android handset makers.

• Healthcare conferences and pipeline trackingHealthcare Tour and ASCO abstract observations

  Judge the quality of China healthcare innovation by combining company field research, clinical data milestones, and BD trends.

  The report emphasizes the commercialization of AIDD, upgraded innovative pipelines, technological routes such as multispecific antibodies and ADCs, and ASCO data from companies including Akeso, Kelun Biotech, Innovent, and CStone.

• Scenario analysisInsurance solvency scenario analysis

  Use a steepening bond yield curve scenario to assess solvency pressure on small and mid-sized insurers.

  The report warns that Chinese SMid insurers may be affected by changes in the interest-rate environment and that capital adequacy and solvency sensitivity should be monitored.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• HashKey (3887.HK)

  Core positive stock; J.P. Morgan upgraded it to Overweight.

  Strengths

  Trading volume is growing year over year, Hong Kong market penetration remains low, gross margin is expected to improve as market-making costs normalize, and RWA, stock tokenization, and stablecoin initiatives provide medium-term structural upside.

  Weaknesses

  System-wide trading activity remains soft, and the digital asset business is sensitive to market risk appetite and the regulatory cycle.

  Comparison

  The stock has fallen 17% since late March while the HSI rose 3% over the same period; the report argues that the pullback plus positive feedback creates better risk/reward.

  Risks

  Digital asset regulation, trading volume volatility, the speed of RWA implementation, stablecoin policy, and platform execution risk.

• China Technology AI enablers / Iuvatar CoreX / Naura / AMEC / Luxshare / Cowell

  Beneficiary assets under the AI and localization theme.

  Strengths

  Domestic AI chips are expected to ramp in 2H26, WFE and OSAT suppliers are more direct beneficiaries, and strong iPhone sales could provide upside surprises for suppliers.

  Weaknesses

  Price increases in upstream materials and services may drag on downstream company margins, and Android handset makers remain in a pressure cycle.

  Comparison

  Upstream equipment, packaging/testing, and AI chip chains are relatively better positioned than downstream consumer electronics and the Android chain.

  Risks

  AI chip ramp-up below expectations, sharper-than-expected increases in memory/foundry/OSAT prices, weak end demand, and export or supply-chain restrictions.

• China Healthcare / Kelun Biotech (6990.HK) / Akeso / Innovent / CStone

  Core theme of healthcare innovation and ASCO data catalysts.

  Strengths

  AIDD is moving from concept to verifiable commercialization, biotech pipelines are shifting from fast-follow to deeper innovation, BD supports financing and global expansion, and advanced technologies such as surgical robots and oncology biomarkers are being adopted more quickly in hospitals.

  Weaknesses

  Clinical data, commercialization revenue, and BD execution still need validation.

  Comparison

  Multispecific antibodies and ADCs remain key focus areas for Chinese companies at ASCO'26.

  Risks

  Clinical failure, regulatory approval, reimbursement/payment pressure, BD terms below expectations, and overseas market access risk.

• China Gas Utilities / Kunlun / CR Gas

  Sector view remains cautious.

  Strengths

  Industrial gas volume improved in April, with support from certain industries and export-related demand, while dollar gross spread has been broadly stable year to date.

  Weaknesses

  4M26 retail gas volume was broadly flat, residential and commercial demand was dragged by a warm winter and weak consumption, new connections were weak, and integrated services and integrated energy businesses are running below the pace implied by full-year guidance.

  Comparison

  Compared with structural themes in technology and healthcare, gas utilities lack clear upside momentum in volume and margins.

  Risks

  Winter gas sourcing costs, LNG prices, weak end demand, continued declines in new connections, and margin pressure.

• Futu Holdings (FUTU)

  Downgraded to Neutral, with the main risk being China cross-border regulatory enforcement.

  Strengths

  Clarification of the fine and share buybacks may help stabilize the stock price, and investor views remain divided.

  Weaknesses

  Regulatory uncertainty in cross-border business weighs on valuation and growth expectations.

  Comparison

  Compared with HashKey’s structural upgrade, Futu is more constrained by regulatory risk scenarios.

  Risks

  Regulation of cross-border securities services, slower customer growth, further valuation compression, and earnings forecast downgrades.

• Bilibili (9626.HK / BILI)

  Overweight; the report describes it as a 0.5x PEG compound earnings growth asset.

  Strengths

  The combination of valuation and earnings growth is considered attractive, and the report uses the term “accumulate.”

  Weaknesses

  The main text does not provide a detailed operational breakdown, so validation depends on subsequent single-stock reports.

  Comparison

  Within consumer internet, it is listed as a more constructive name rather than a broker platform dominated by regulatory risk.

  Risks

  User growth, game/advertising monetization, earnings delivery, and shifts in market risk appetite.

• Lenovo Group (0992.HK)

  Neutral, with company results and view update.

  Strengths

  ISG turnaround provides upside, and initial observations for 4Q FY26 indicate earnings beat expectations and PC margins were better than feared.

  Weaknesses

  The report highlights the risk of a PC cycle reset in 2H.

  Comparison

  Compared with upstream AI enablers, Lenovo benefits from improving server operations but remains exposed to the PC cycle.

  Risks

  PC demand slowdown, unsustained recovery in server business, margin pressure, and intensifying competition.

• Sungrow (300274.SZ)

  Overweight, supported by the Emerging AIDC ESS Opportunities theme.

  Strengths

  Energy storage demand related to AI data centers may become a new opportunity.

  Weaknesses

  The main text only provides the title and does not disclose detailed financial or order data.

  Comparison

  It sits at the intersection of AI computing infrastructure and energy storage, distinguishing it from the low-growth narrative of traditional utilities.

  Risks

  Slower data center capex, energy storage price competition, project delivery, and policy risk.

• China Pacific Insurance (2601.HK)

  Overweight, one of the company meeting feedback items in the insurance sector.

  Strengths

  The report title emphasizes a focus on underwriting quality and a cautious stance toward 2026 interim dividends.

  Weaknesses

  The insurance sector as a whole still needs to monitor interest-rate and capital pressure.

  Comparison

  Large insurers and SMid insurers may face different solvency pressures, requiring differentiation in balance-sheet strength and dividend capacity.

  Risks

  A steepening bond yield curve, solvency pressure, investment income volatility, and dividend uncertainty.

• H World Group (1179.HK / HTHT)

  Overweight, one of the constructive names in consumer/hotels.

  Strengths

  The report title says the long-term growth algorithm remains intact, with a one-brand/two-engine model continuing to compound.

  Weaknesses

  The main text does not disclose detailed occupancy, RevPAR, or store expansion data.

  Comparison

  Compared with weak consumption dragging commercial gas demand, hotel chains are still included in Overweight company updates.

  Risks

  Consumption recovery below expectations, hotel supply competition, store expansion quality, and macro cycle risk.

Key data

• Summit scaleMore than 2,900 delegates, 35 jurisdictions/markets, and over 300 companies in one-on-one meetingsFrom the 2026 J.P. Morgan Global China Summit, held from May 20 to 22.
• Technology chain timingDomestic AI chip suppliers are expected to ramp significantly in 2H26WFE and OSAT suppliers are seen as the main beneficiaries; price increases in upstream memory, wafer foundries, and packaging/testing may compress downstream margins.
• Top technology picksIuvatar CoreX, Naura, AMEC, Luxshare, CowellThe report describes these as top picks in China technology.
• Healthcare field researchVisited multiple AIDD, biotech, and medtech companies in Beijing and Shanghai on May 18-19The report says it turned more positive on the sector after the trip, focusing on AI drug discovery commercialization, differentiated innovation, BD, and hospital adoption of technology.
• ASCO'26 key milestonesConference from May 29 to June 2; Akeso HARMONi-6 OS interim readout expected to be presented on May 31The report also mentions key data from Chinese companies including Kelun Biotech, Innovent, and CStone.
• HashKey rating and target price clues3887.HK, Overweight, HK$3.73The report says HashKey was upgraded to Overweight without changing PT after the stock’s relative pullback since late March.
• HashKey operating cluesManagement expects gross margin to expand by about 10 percentage points year over year; stock tokenization may gain traction within 6-12 monthsThe report also mentions RWA, stablecoins, improving retail mix, and operating leverage.
• Gas utilities4M26 retail gas volume was broadly flat, and new connections remained weakResidential/commercial demand was dragged by a warm winter and weak consumption, while industrial gas volume improved in April but the overall trend remained subdued.
• Relative market performanceHashKey has fallen 17% since late March, versus a 3% gain in the HSI over the same periodThe report cites the post-pullback risk/reward and positive summit feedback as the backdrop for the upgrade.

Impact & implications

For portfolios, the report supports continued focus on China’s structural growth themes, especially domestic AI computing infrastructure, semiconductor equipment/packaging and testing, healthcare innovation, and digital asset infrastructure; at the same time, positive summit feedback should not be extrapolated simplistically to all sectors. Utilities, downstream consumer electronics, cross-border internet brokers, and small and mid-sized insurers carry higher risk exposure. From an allocation perspective, it is more appropriate to differentiate between upstream beneficiaries, companies with clear catalysts, and companies whose earnings/regulatory pressures have yet to ease.

Risks

• China cross-border regulatory enforcement may weigh on valuation and growth for cross-border financial platforms such as Futu.
• Price increases in memory, wafer foundry, and OSAT may drag on margins for downstream consumer electronics companies, and pressure on Android handset makers may not have bottomed yet.
• Healthcare innovation companies face uncertainty around clinical readouts, approvals, commercialization, and BD execution.
• Gas utilities face risks from a warm winter, weak consumption, industrial demand volatility, LNG prices, and winter gas sourcing costs.
• A steepening bond yield curve may trigger solvency concerns for Chinese small and mid-sized insurers.
• Digital assets, RWA, and stablecoin themes are highly sensitive to regulatory policy, market risk appetite, and the pace of technology implementation.
• The report is an email-style research summary, and some companies are covered only at the headline level; detailed valuation and risks require reviewing the full single-stock reports.

What to watch

• Whether domestic AI chip supplier shipment ramp-up materializes in 2H26.
• Changes in orders, capacity utilization, and gross margins for WFE and OSAT companies.
• The impact of upstream memory, wafer foundry, and packaging/testing price changes on consumer electronics company margins.
• Key data at ASCO'26 including Akeso HARMONi-6 OS, Kelun Biotech sac-TMT, Innovent IBI363, and CStone CS2009.
• HashKey’s 6-12 month progress in trading volume, year-over-year gross margin expansion, stock tokenization, RWA, and stablecoin initiatives.
• China gas utilities’ retail gas volume, new connections, industrial gas demand, winter gas sourcing costs, and LNG prices.
• Follow-up on Futu cross-border regulatory enforcement, fine implementation, buyback execution, and changes in customer activity.
• Orders related to AI data center energy storage, computing infrastructure, and utility capital expenditure.
• Insurers’ solvency and interim dividend arrangements under a steepening bond yield curve scenario.